Reduce Radiation | Abbott
CARDIOVASCULAR
hamburger
Reduce Radiation

Reduce the long-term dangers of radiation exposure and orthopedic injuries caused by fluoroscopy by adopting the world’s most widely used and published solution for intracardiac echo, transseptal access, and ablation support1 in a low-fluoro workflow.

Reduce Fluoro Exposure


REDUCE FLUORO
EXPOSURE

Reduce Procedure Time


REDUCE
PROCEDURE TIME

Improve Case Margins


IMPROVE CASE
MARGINS

Reduce Fluoro Exposure

By an average of
6.95 MINUTES2
through ICE-guided ablation using ViewFlex™ Xtra ICE Catheter

6.95 Minutes

By 27%
(33 min vs 45 min)3 with Agilis™ NxT Steerable Introducer

27%

Reduce Procedure Time

By an average of
15.2 MINUTES2
through ICE-guided ablation using ViewFlex™ Xtra ICE Catheter

15.2 minutes

By 32%
(30.4 min vs 44.6 min)4 with Agilis™ NxT Steerable Introducer

32%

Improve Case Margins


ENABLE EFFICIENT AND ECONOMICAL ACCESS
capitalizing on the competitive price offered with the combined use of ViewFlex Xtra ICE Catheter, Agilis NxT Steerable Introducer, and BRK™ Transseptal Needle, XS Series

Improve Case Margins

Reduce Radiation: The Complete Low-Fluoro Solution

ViewMate™ Ultrasound Console & ViewFlex™ Xtra ICE Catheter

ViewMate Ultrasound Console & ViewFlex Xtra ICE Catheter

421,000+

PROCEDURES WORLDWIDE1
 


Offers enhanced resolution with outstanding image quality

Enhanced Resolution


Reduce complications with ICE-guided ablation

Enhanced Resolution

CARDIAC COMPLICATIONS6

Such as pericardial effucsion, tamponade, thrombus formation, pulmonary vein stenosis, with microbubbles detected as a result of overheating.2

59%

Agilis™ NXT Steerable Introducer

Agilis Nxt Steerable Introducer

1,600,000+

PROCEDURES WORLDWIDE1
 

Choose the Gold Standard

Tailor to your patient’s anatomy with a large variety of sizes & curves that maintain their shape.

Gold Standard

Confident Steering and Stable Positioning with Exceptional Maneuverability

Access hard-to-reach areas with precise maneuverability and auto-lock steering, such as the right inferior and left anterior pulmonary veins7

Confident Steering and Stable Positioning

Reliable, Complete Lesion Creation Through Outstanding Agility and Stability

Lesion Creation

GREATER FREEDOM FROM ARRHYTHMIA AT 6 MONTHS

(76.0% vs 53.0%)3 and 18% greater at 12 months (74.0% vs 62.7%)8

43%

BRK™ Transseptal Needle, XS Series

BRK Transseptal Needle, XS Series

2,600,000+

PROCEDURES WORLDWIDE1
 

Go Transseptal Efficiently and Economically

Experience the consistency, reliability and flexibility of the world’s most widely used1 transseptal needle design

Go Transseptal

Proven Performance in Varied Anatomies

  • A steeper angle of approach with two curve styles: the standard BRK Transseptal Needle, XS Series curve or the BRK-1™ Transseptal Needles, XS Series curve
  • Procedural accuracy with three usable lengths: 71cm, 89cm, 98cm
Proven Performance

Watch a Low-Fluoro Case and Workflow

View Dr. Arjun Gururaj, MD as he utilizes ViewFlex™ Xtra ICE Catheter, in conjunction with the EnSite Precision™ Cardiac Mapping System, to minimize fluoro usage in this re-do AF Ablation case. Dr. Gururaj performs a double-transseptal under ICE guidance, while highlighting various structures and views to assist in a low-fluoro workflow throughout the case.

Supported by Abbott: Your Single-Source EP Solution

The low-fluoro portfolio is integrated with Abbott’s leading electrophysiology solutions offering a broad range of product sizes, curves, and accessories to tailor to nearly any patient anatomy and clinician preference.

4.6+ MILLION

UTILIZATIONS1

Abbott's portfolio is the world's most widely used solution for intracardiac echo, transseptal access, and ablation support

EXTENSIVE

CLINICAL DATA

Robust publications demonstrating proven patient outcomes, procedural efficiency, and accuracy

IMPORTANT SAFETY INFORMATION

Agilis™ NxT Steerable Introducer
BRK™ Transseptal Needle, XS Series
ViewFlex™ Xtra ICE Catheter and ViewMate™ Ultrasound Console

References

  1. Abbott internal data on file PULSE data.
  2. Goya M, et al. The use of intracardiac echocardiography catheters in endocardial ablation of cardiac arrhythmia: Meta-analysis of efficiency, effectiveness, and safety outcomes. J Cardiovasc Electrophysiol. 2020;31:664–673.
  3. Piorkowski C, et al. (2011). Steerable versus non-steerable sheath technology in AF ablation: A prospective, randomized study. Circulation, 4(2), 157–165.
  4. Matsuo S, et al. (2010). Prospective randomized comparison of a steerable versus a non-steerable sheath for typical atrial flutter ablation. Europace, 12(3), 402–409.
  5. Casella M, et al. (2015). Near zero fluoroscopic exposure during catheter ablation of supraventricular arrhythmias: the NO-PARTY multicentre randomized trial. Europace (2016) 18, 1565–1572. doi:10.1093/europace/euv344
  6. Aldhoon B, et al. Complications of catheter ablation for atrial fibrillation in a high-volume centre with the use of intracardiac echocardiography. Europace (2013) 15, 24–32.
  7. Piorkowski C, et al. (2008). Steerable sheath catheter navigation for ablation of atrial fibrillation: A case-control study. Pacing and Clinical Electrophysiology, 31(7), 863–873.
  8. Mansour M. (2014). TOCCASTAR: Preliminary Results of the First Prospective Randomized Study of a Contact Force Sensing Ablation Catheter for the Treatment of Paroxysmal AF. Presented at HRS AF Summit 2014. San Francisco, California.

MAT-2214183 v1.0

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

False
accessibility
© 2021 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.